Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q4 FY25 results · Jan–Mar 2025
Aarti Pharmalabs reported revenue from operations of ₹563.78 crore (up 11.5% from Q4 FY24) and net profit of ₹88.34 crore (up 35.4% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 563.78 | 505.77 | +11.5% | 537.78 | +4.8% |
| Other income | (1.61) | 2.03 | Turned loss | 5.03 | Turned loss |
| Total income | 562.17 | 507.80 | +10.7% | 542.81 | +3.6% |
| Profit before tax | 114.62 | 95.75 | +19.7% | 100.63 | +13.9% |
| Net profit for the period | 88.34 | 65.25 | +35.4% | 73.99 | +19.4% |
| EPS, basic (₹) | 9.75 | 7.20 | +35.4% | 8.16 | +19.5% |
| Net margin (%) | 15.7 | 12.9 | 13.8 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 529.62 | 414.82 | +27.7% | 470.95 | +12.5% |
| Other income | (2.50) | 5.69 | Turned loss | 11.94 | Turned loss |
| Total income | 527.12 | 420.50 | +25.4% | 482.88 | +9.2% |
| Profit before tax | 113.50 | 91.28 | +24.3% | 96.18 | +18.0% |
| Net profit for the period | 88.85 | 63.02 | +41.0% | 73.52 | +20.8% |
| EPS, basic (₹) | 9.80 | 6.95 | +41.0% | 8.11 | +20.8% |
| Net margin (%) | 16.8 | 15.2 | 15.6 |
Consolidated
- Filed with BSE
- 10 May 2025, 21:29 IST
- Board meeting
- 10 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 May 2025, 21:29 IST
- Board meeting
- 10 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE